ClinicalTrials.gg
CompletedNCT01999101Updated Sep 29, 2016

Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients

A Phase 2 interventional study of Px-104 in Non Alcoholic Fatty Liver Disease, sponsored by Phenex Pharmaceuticals AG. Completed at 1 site in Austria. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-09-29.

Sponsored by Phenex Pharmaceuticals AG · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Non-alcoholic Fatty Liver Disease with a site in Austria — 5 open to participants now, 8 under way, 4 of them phase 3. Non-alcoholic Fatty Liver Disease · Austria.

Enrollment
23rd of 24
12 · median 308
Started
2013
with 1 other
Phase 2
8 of 28
1 open now
Registered
3rd of 28
by date

Among the 28 studies in Non-alcoholic Fatty Liver Disease with a site in Austria, this one is the 23rd largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2013, is one of 8 in phase 2, and was the 3rd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

5 of the 28 studies in Non-alcoholic Fatty Liver Disease with a site in Austria are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Non-alcoholic Fatty Liver Disease with a site in Austria, or all of them as a file.
02

Study summary

The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD patients and to assess the influence of Px-104 on hepatic fat.

03

Conditions studied

  • Non Alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NAFLD patients
  • Weight > 65 kg
  • > 25 and \< 40
  • Negative blood or urine pregnancy test (for females of ) collected at screening followed by another negative serum pregnancy test collected within 24 hours prior to the first dose of study drug.
  • : Female patients must be , surgically sterile, or if premenopausal, must be prepared to use at least two effective (≤1% failure rate) method of contraception during the course of the study and for 14 days after the end of dosing. Male patients with female partners of child bearing potential must be prepared to use at least two effective methods of contraception with all sexual partners unless they have had a prior vasectomy
  • Must be willing and able to give written and agree to comply with the study protocol.
  • Sinus rhythm in 12-lead

Exclusion criteria

Exclusion Criteria:

  • Evidence of excessive alcohol, drug or substance abuse (excluding marijuana use) within 1 year of first dose.
  • History or other evidence of a medical condition associated with chronic liver disease other than.
  • History or other evidence of decompensated liver disease ( Grade B or higher), coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites, hepatic encephalopathy, and bleeding from esophageal varices are conditions consistent with decompensated liver disease.
  • Concomitant intake of fibrates or statins (at least 4-6 weeks before start; considering half life of medication).
  • Any findings in (identified via 24h-Holter ECG or 12-Lead ECG) at screening
  • History of any structural cardiac disease.
  • In addition, patients with documented or presumed unstable coronary artery disease, stable or unstable cardiovascular disease or cerebrovascular disease.
  • One or more of the following conditions: (1) poorly controlled hypertension, OR (2) screening or baseline blood pressure ≥ 160 mmHg for systolic OR (3) screening or baseline blood pressure ≥ 100 mmHg for diastolic blood pressure.
  • Type I or II diabetes with > 6.5% at screening and/or fasting plasma glucose > 7mmol/L (> 126 mg/dl).
  • History or other evidence of a clinically relevant ophthalmologic disorder due to diabetes mellitus or hypertension or history or other evidence of severe retinopathy (e.g., cytomegalovirus, macular degeneration).
  • Known sensibility to any ingredients contained in the medicinal product (IMP)
  • All conditions that do not allow magentic resonance (MR) assessments
  • History of having received any investigational drug ≤ 3 months and/or 6 x half-life prior to the first dose of study drug or the expectation that such drugs will be used during the study. Patients enrolled in this study cannot be enrolled in another study for either research, diagnostic or treatment purposes.
  • Woman with unless using adequate (see inclusion criteria); females who are pregnant or breast feeding.
  • History of severe allergic
  • Evidence of an active or suspected cancer, or a history of within the last 2 years, with the exception of patients with basal cell carcinoma that has been excised and cured.
  • History of any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of and radiation) 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
  • History of bleeding disorders or anticoagulant use
  • History or other evidence of chronic pulmonary disease associated with functional limitation.
  • History of uncontrolled severe seizure disorder.
  • Poorly controlled thyroid dysfunction.
  • History of major organ transplantation with an existing functional graft.
  • Any signs of acute infection or inflammation
  • History or other evidence of severe illness, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
  • Any herbal supplements containing silymarin, tocopherol, vitamin C, riboflavins, proflavins, curcumin. (at least 4-6 months before the study)
  • Positive test at screening for anti-Hepatits A virus (HAV) Immunoglobulin M (IgM), Hebatitis B surface antigen (), Anti-Hepatits B core Antigen Immunglobulin M antibody (anti-HBc IgM Ab), or anti- Ab.
  • Subjects who have undergone surgery within the last 3 months.
  • Subjects who have had a prior gastrointestinal surgery.
  • Subjects who will be unavailable for the duration of the trial, who are unlikely to be compliant with the protocol, or who are felt to b unsuitable by the investigator for any other reason
  • Imprisonment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Px-104

    Px-104 capsules, 5 mg

    Drug: Px-104

Interventions

06

What researchers measure

Primary outcomes

  1. Safety

    Analysis of clinical chemistry, hematology, and assessment of clinical signs and adverse events over 28 days. Change day 28 vs. day 1

    Time frame: 28 days

Secondary outcomes

  1. Change of hepatocellular lipid content

    Measurement of hepatic fat (%) by Magnetic resonance spectroscopy (MRS), change day 28 vs. day 1

    Time frame: day 1 and day 28

  2. Changes in oral glucose tolerance test (oGTT)

    Measurement of plasma glucose level (mg/dL)

    Time frame: baseline and day 27

  3. Change from baseline in fibroblast growth factor 19 (FGF-19)

    Measurement by ELISA (pg/mL)

    Time frame: days 1, 7, 14, 21 and 28

  4. Change from baseline in plasma bile acid concentration

    Assessment by LC-MS/MS (µmol/L)

    Time frame: days 1, 7, 14, 21, and 28.

  5. Pharmacokinetics of Px-104 and conjugates

    Measurement by LC-MS/MS (ng/mL). AUC, Cmax and other pk parameters

    Time frame: day 1 and day 28

Other outcomes

  1. Changes in the Saccharose-Lactulose-Mannitol + Sucralose (SLM+S) Test to evaluate the intestinal permeability

    Measurement of urinary concentrations of Saccharose, Lactulose, Mannitol and Sucralose by HPLC

    Time frame: baseline and day 27

  2. Assessment of liver steatosis by CAP-Fibroscan

    Measurement of hepatic fat (%) by CAP-Fibroscan

    Time frame: baseline and day 28

07

Study locations

1 site
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III
    Vienna, 1090, Austria
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jan 2015 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2013
First posted
Dec 3, 2013
Start
Oct 2013
Primary completionActual
Jan 2015
CompletionActual
Jun 2016
Last update
Sep 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01999101
Lead sponsor
Phenex Pharmaceuticals AG
Responsible party
Sponsor
First posted
Dec 3, 2013
Start date
Oct 2013
Primary completion
Jan 2015
Completion
Jun 2016
Last update
Sep 29, 2016

Study contacts

Michael Trauner, Professor Dr med
principal investigator · Medical University Vienna

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilofexor

Start the discussion